McCann, Georgia A.
Mayo Clinic
The University of Texas at San Antonio Health Science Center
Citations 2
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Vinayak, Shaveta , Tolaney, Sara M. , Mita, Monica , McCann, Georgia A., Tan, Antoinette R. , Wahner-Hendrickson, Andrea E., Forero, Andres , Anders, Carey K. , Wulf, Gerburg M. , Zarwan, Corrine, Erban, John K. , Zhou, Yinghui , Buerstatte, Nathan, Graham, Julie R. , Arora, Sujata, Dezube, Bruce J., Telli, Melinda L. , Wulf, Gerburg M , Schwartzberg, Lee Steven , Dillon, Patrick Michael , Lynce, Filipa , Telli, Melinda L
JAMA Oncology | June 13, 2019 | Volume: 5 | Issue: 8 | Pages: 1132
TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
Vinayak, Shaveta , Tolaney, Sara M. , Mita, Monica , McCann, Georgia A., Tan, Antoinette R. , Hendrickson, Andrea E. Wahner , ForeroâTorres, Andres , Zarwan, Corrine, Erban, John K. , Dezube, Bruce J., Zhou, Yinghui , Buerstatte, Nathan, Arora, Sujata, Achour, Haroun, Telli, Melinda L. , Schwartzberg, Lee Steven , Anders, Carey K. , Wulf, Gerburg M. , Dillon, Patrick Michael , Lynce, Filipa , Telli, Melinda L
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1011-1011